SCHEMBL4636191

SCHEMBL4636191

COC(=O)c1cccc(O)c1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC28A3 Q9HAS3 2/20 0.61
POLB P06746 1/20 0.54
SLC5A1 P13866 2/20 0.52
APP P05067 1/20 0.52
EPHX2 P34913 1/20 0.52
HIF1A Q16665 1/20 0.51
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA7 P43166 1/20 0.49
CA9 Q16790 1/20 0.49
CA13 Q8N1Q1 1/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
SLC5A2 P31639 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4636160 0.89 SLC28A3 (0.58) SLC28A3POLBSLC5A1EPHX2HIF1A
SCHEMBL4635629 0.88 SLC28A3 (0.57) SLC28A3SLC5A1EPHX2HIF1ACA12
SCHEMBL4635305 0.87 SLC28A3 (0.61) SLC28A3SLC5A1EPHX2HIF1ANPC1
SCHEMBL4635870 0.87 SLC28A3 (0.56) SLC28A3SLC5A1EPHX2HIF1ACA12
SCHEMBL14128555 0.85 POLB (0.54) SLC28A3POLBEPHX2
SCHEMBL942732 0.85 SLC28A3 (0.62) SLC28A3SLC5A1APPHIF1ASLC5A2
SCHEMBL940443 0.83 SLC28A3 (0.78) SLC28A3SLC5A1APPHIF1A
SCHEMBL29078207 0.82 SLC28A3 (0.64) SLC28A3POLBSLC5A1EPHX2HIF1A
SCHEMBL5191128 0.81 SLC28A3 (0.55) SLC28A3POLBAPPCA12CA1
SCHEMBL30803032 0.79 SLC28A3 (0.53) SLC28A3SLC5A1EPHX2HIF1ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1932514-B1 PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR EZAKI GLICO CO (JP) 2018-11-14 EP disclosed
US-20140023602-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE EZAKI GLICO CO., LTD. (JP) 2014-01-23 US disclosed
US-20080274068-A1 External Preparation for Skin Containing a Phosphorlated Saccharide EZAKI GLICO CO., LTD. (JP) 2008-11-06 US disclosed
EP-1932514-A1 PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR Ezaki Glico Co., Ltd. (JP) 2008-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140023602-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE SI, CUTA, CD44 SLC28A3 1164/4885POLB 2842/4885SLC5A1 723/4885
US-20080274068-A1 External Preparation for Skin Containing a Phosphorlated Saccharide CUTA, SI, CD44 SLC28A3 977/4885POLB 2671/4885SLC5A1 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.